Investor Relations

Corporate Overview

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures and CNS disorders for both hospital and home settings.

Read more

Why Invest


Years of combined industry experience


SE is the second most common CNS emergency in the US


Patients safely treated using therapeutically relevant doses of ganaxolone


Potential treatment for status epilepticus and other rare epilepsies that have few or no treatment options

Latest News

View all news

Latest Presentation

Latest Events

View All Events

Latest Quarterly Reports

View All Financial Reports